AbbVie Inc (ABBV)vsTheravance Biopharma Inc (TBPH)
ABBV
AbbVie Inc
$253.35
+4.20%
HEALTHCARE · Cap: $447.62B
TBPH
Theravance Biopharma Inc
$17.63
-0.49%
HEALTHCARE · Cap: $908.88M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 57125% more annual revenue ($62.82B vs $109.78M). TBPH leads profitability with a 104.3% profit margin vs 5.8%. TBPH trades at a lower P/E of 7.9x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
TBPH
Hold47
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.3%
Fair Value
$146.22
Current Price
$253.35
$107.13 premium
Margin of Safety
+67.3%
Fair Value
$59.74
Current Price
$17.63
$42.11 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Attractively priced relative to earnings
Every $100 of equity generates 39 in profit
Keeps 104 of every $100 in revenue as profit
Conservative balance sheet, low leverage
15.0% revenue growth
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Distress zone — elevated risk
Operating margin of -33.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : TBPH
The strongest argument for TBPH centers on P/E Ratio, Return on Equity, Profit Margin. Profitability is solid with margins at 104.3% and operating margin at -33.1%. Revenue growth of 15.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 123.6x leaves little room for execution misses.
Bear Case : TBPH
The primary concerns for TBPH are EPS Growth, Market Cap, Altman Z-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while TBPH is a mature play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.31 — expect wider price swings.
TBPH is growing revenue faster at 15.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 47/100) and 12.4% revenue growth. TBPH offers better value entry with a 67.3% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Theravance Biopharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe, and Asia. The company is headquartered in George Town, the Cayman Islands.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?